%0 Journal Article %A A. Cividjian %A F Wallet %A C. Guichon %A O. Martin %A S. Couray-Targe %A T Rimmelé %A PF Wey %T Simplified model of the number of Covid-19 patients in the ICU: update April 6, 2020 %D 2020 %R 10.1101/2020.04.07.20056226 %J medRxiv %P 2020.04.07.20056226 %X INTRODUCTION Predicting the number of Covid-19 patients in the Intensive Care Units (ICU) could be useful to avoid the breaking point. We attempted to deduce a formula in order to model the number of the ICU patients in France from the official data and patient turnover in the ICU.METHODS The Covid-19 ICU patient turnover was calculated using a recurrence relation from the internal data provided by Hospices Civils de Lyon. The number of new Covid-19 cases detected daily was modelized to fit with the last known data in France and extrapolated for the coming days using two scenarios following the existing data in China (best scenario) and Italy (worst scenario). The number of daily admissions in ICU was calculated as the sum of 13.7% of the new Covid-19 cases detected on a given day and 7.8% of the average of the total new Covid-19 cases recorded in the last week. Approximately 39.7% of patients admitted to the ICU were non-intubated with an average ICU length of stay of 4 days. Conversely, 60.3% of patients were intubated and for those who died among them (14.44%) the ICU length of stay was of 4 days for 78.3% of them and of 15 days for 21.7% of them. For the intubated patients that were discharged alive, the ICU length of stay was of 6 days for 44.4% of them and of 20 days for 55.6% of them.RESULTS We predict a peak of 7072 – 8043 patients for the overall French territory.CONCUSION Despite a simplified mathematical model, the strength of our study is a narrow possible range of predicted total number of ICU patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot a clinical trialFunding Statementno external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesExcel formulas are available on request %U https://www.medrxiv.org/content/medrxiv/early/2020/04/11/2020.04.07.20056226.full.pdf